For Health Care
GRETALS originally pursued significant opportunities in combating the rapidly escalating & global antimicrobial resistance crisis by identifying & developing innovative antimicrobial formulations. This development evolved upon the discovery of high volumes of a particular flavanone. Upon researching into the ability of this compound, especially its clinically proven action of crossing the blood-brain-barrier in humans, the opportunity to grow & progress the business model has ensued. The previous rate-limiting-factor has been the lack of supply of this unique compound.
An extension of these developments has led to the discovery of significant findings that have a bearing on offering treatment for the current pandemic affecting the world. The company is seeking interest from the pharmaceutical industry to take these discoveries to commercial end points.